[1]
|
Wilson, M.K., Mercieca-Bebber, R. and Friedlander, M. (2018) Apractical Guide to Understanding, Using and Including Patient Reported Outcomes in Clinical Trials in Ovarian cancer. Journal of Gynecologic Oncology, 29, Article No. e81. https://doi.org/10.3802/jgo.2018.29.e81
|
[2]
|
Miyamae, Y., Shimizu, H., Naganuma, A., Aiba, M., Tanaka, T., Ogawa, T., et al. (2016) A Case of Rectal Neuroendocrine Carcinoma with Metachronous Liver Metastasis Treated with Multimodality Therapy. Japanese Journal of Cancer and Chemotherapy, 43, 1009-1013.
|
[3]
|
黄少江. 贝伐单抗联合新辅助化疗治疗晚期卵巢癌临床效果分析[J]. 中国医学前沿杂志(电子版), 2017, 9(6): 109-112.
|
[4]
|
Weiderpass, E. and Tyczynski, J.E. (2015) Epidemiology of Patients with Ovarian Cancer with and without a BRCA1/2 Mutation. Molecular Diagnosis & Therapy, 19, 351-364. https://doi.org/10.1007/s40291-015-0168-x
|
[5]
|
刘宏侠, 李万斌, 韩树斋. 贝伐珠单抗联合化疗治疗复发性卵巢癌的疗效分析[J]. 癌症杂志, 2018, 16(14): 1790- 1793.
|
[6]
|
Jayson, G.C., Kerbel, R., Ellis, L.M. and Harris, A.L. (2016) Antiangiogenic Therapy in Oneology: Current Status and Future Directions. Lancet, 388, 518-529. https://doi.org/10.1016/S0140-6736(15)01088-0
|
[7]
|
Wang, J., Chen, J., Guo, Y., Wang, B. and Chu, H. (2017) Strategies Targeting Angiogenesis in Advanced Non-Small Cell Lung Cancer. Onco-target, 8, 53854-53872. https://doi.org/10.18632/oncotarget.17957
|
[8]
|
张洁. 抗血管生成药物联合化疗在复发性卵巢癌治疗中的研究进展[J]. 国妇产科学杂志, 2016, 43(1): 70-74.
|
[9]
|
Bhagat, P.R., Agrawal, K.U. and Tandel, D. (2016) Study of the Effect of Injection Bevacizumab through Various Routes in Neovascular Glaucoma. Journal of Current Glaucoma Practice, 10, 39-48.
https://doi.org/10.5005/jp-journals-10008-1200
|
[10]
|
马小莲, 郑德友, 何吉庆. 贝伐珠单抗注射液联合紫杉醇注射液和顺铂注射液治疗卵巢癌的临床研究[J]. 中国临床药理学杂志, 2018, 34(23): 2697-2699+2703.
|
[11]
|
郜晓, 宋丽丽, 朱凯, 陈洁. 贝伐单抗联合白蛋白结合型紫杉醇治疗铂类耐药的复发性卵巢癌的临床效果观察[J]. 中国综合临床, 2018, 34(3): 209-214.
|
[12]
|
温娜, 边立华, 龚静, 孟元光. 白蛋白结合型紫杉醇与紫杉醇脂质体治疗晚期和复发子宫颈癌患者的临床疗效对照研究[J]. 实用妇科杂志, 2018, 34(12): 935-938.
|
[13]
|
谢宝芬, 潘柏良. 紫杉醇的药理与临床研究进展[J]. 中国药业, 2008, 17(15): 76-78.
|
[14]
|
汪玲莉. 紫杉醇注射液联合顺铂注射液治疗晚期卵巢癌的临床研究[J]. 中国临床药理学杂志, 2018, 34(17): 2039-2041.
|
[15]
|
李常虹, 章小娟, 谢曼, 黄翎. 紫杉醇联合奈达铂治疗晚期卵巢癌患者的临床研究[J]. 中国临床药理学杂志, 2019, 35(18): 2036-2039.
|
[16]
|
程海荣, 关慧, 陈杰. 白蛋白结合型紫杉醇与紫杉醇脂质体治疗复发性卵巢癌近期疗效与安全性分析[J]. 实用妇产科杂志, 2015, 31(3): 229-232.
|
[17]
|
Chakravarthi, S.S., De, S., Miller, D.W. and Robinson, D.H. (2010) Comparison of Antitumor Efficacy of Paclitaxel Delivered in Nano and Microparticles. International Journal of Pharmaceutics, 383, 37-44.
https://doi.org/10.1016/j.ijpharm.2009.09.004
|
[18]
|
Hosein, P.J., De Lima Lones Jr., G., Pastorini, V.H., Gomez, C., Macintyre, J., Zayas, G., et al. (2013) A Phase II Trial of Nab-Paclitaxel as Second-Line Therapy in Latients with Advanced Panereatier. American Journal of Clinical Oncology, 36, 151-156. https://doi.org/10.1097/COC.0b013e3182436e8c
|
[19]
|
思美丽, 吴文湘. 白蛋白结合型紫杉醇与紫杉醇脂质体治疗复发性卵巢癌的临床研究[J]. 实用癌症杂志, 2018, 33(3): 507-509.
|